The aggressive nature of peripheral T-cell lymphoma (PTCL), its conventional treatment resistance, and absence of specific therapies available complicate the management of PTCL. Protheragen has extensive experience with developing PTCL therapies which allows us to assist you throughout the entire process from your PTCL therapy research to its commercial use.
Peripheral T-cell lymphoma (PTCL) is a clinically and histologically heterogeneous group of T-cell lymphomas occurring outside the thymus and bone marrow. This subtype of non-Hodgkin lymphoma includes entities such as cutaneous T-cell lymphomas (CTCL), angioimmunoblastic T-cell lymphoma (AITCL), and anaplastic large cell lymphoma (ALCL). PTCL is particularly difficult to manage owing to its diversity and aggressive nature.
Fig.1 The classification of peripheral T-cell lymphoma (PTCL). (Pu, Qiyao, et al., 2022)
The pathogenesis of peripheral T-cell lymphoma (PTCL) is associated with various molecular changes, including the signaling pathways JAK-STAT and NF-κB, in addition to mutations in TET2 and DNMT3A which drives uncontrolled T-cell proliferation. Also, immune-evasion mechanisms such as PD-L1 expression facilitate immune evasion, whereas the tumor microenvironment remains crucial for PTCL progression. Addressing the biological factors behind immune dysregulation and molecular changes offers new opportunities for PTCL therapeutic development.
Fig.2 Selected therapeutic advances in peripheral T-cell lymphomas (PTCLs). (Stuver, Robert, and Alison J. Moskowitz., 2023)
| Therapy | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Lenalidomide + Gemcitabine |
|
Cereblon/DNA/RNA | NCT05105412 | Phase Ib/II |
| HBI-8000 |
|
HDACs | NCT02953652 | Phase IIb |
| Chidamide |
|
HDACs | NCT06550336 | Phase II |
| Romidepsin + Pralatrexate |
|
HDACs/DHFR | NCT03355768 | Phase I/II |
| Ixazomib + Romidepsin |
|
Proteasome/HDACs | NCT03547700 | Phase I/II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen is advancing research in the diagnostics and therapeutics of peripheral T cell lymphoma (PTCL) by striding innovative pathways as a research service provider. We specialize in the development of biomarkers, in vitro diagnostic (IVD) kits, and pro-active therapies detouring PTCL therapeutic cascades. Innovative disease models coupled with preclinical research are employed to stringently validate every potential treatment options.
At Protheragen, we are committed to validating and optimizing therapies for peripheral T-cell lymphoma (PTCL) through preclinical studies including pharmacodynamics (PD), pharmacokinetics (PK) and toxicology to ensure their successful regulatory approval. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)